Clin Nutr Res.  2016 Apr;5(2):89-95. 10.7762/cnr.2016.5.2.89.

Effects of Bread with Nigella Sativa on Lipid Profiles, Apolipoproteins and Inflammatory Factor in Metabolic Syndrome Patients

• Mohtashami A
• Mahaki B
• Azadbakht
• Entezari M

• KMID: 2168226
• DOI: http://doi.org/10.7762/cnr.2016.5.2.89

Abstract

Nigella sativa (N.sativa) has been used in traditional medicine and many studies have been performed in different communities in order to reveal the effects of it on medical disorders and chronic diseases. The aim of this study was to investigate the effects of bread with N. Sativa on lipid profiles, apolipoproteins, and inflammatory factors in metabolic syndrome (MetS) patients. A randomized, double-blind, cross-over and clinical trial was conducted in 51 MetS patients of both sexes with age group of 20-65 years old in Chaloos, north of Iran. Patients were randomly divided in two groups. In phase 1, intervention group (A, n = 27) received daily a bread with N. sativa and wheat bran and control group (B, n = 24) received the same bread without N. sativa for 2 months. After 2 weeks of wash out period, phase 2 was started with switch the intervention between two groups. Measuring of lipid profiles, apolipoproteins and inflammatory factor was performed for all patients before and after two phases. In this study, treatment, sequence and time effects of intervention were evaluated and revealed that consumption of bread with N. sativa has no significant treatment and time effects on triglyceride (TG), cholesterol (CHOL), low density lipoprotein (LDL), high density lipoprotein (HDL), apolipoprotein (APO)-A, APO-B and high-sensitivity C-reactive protein (p > 0.05). Sequence effect was significant on CHOL, LDL, APO-A, and APO-B (p < 0.05) but was not significant on other parameters (p > 0.05). Consumption of bread with N. sativa has no a significant effect on lipid profiles, apolipoproteins and inflammatory factor in MetS patients.

Keyword

Nigella sativa; Lipid profiles; Apolipoproteins; Inflammatory factors; Metabolic syndrome

MeSH Terms

Apolipoproteins A
Apolipoproteins B
Apolipoproteins*
Bread*
C-Reactive Protein
Cholesterol
Chronic Disease
Dietary Fiber
Humans
Iran
Lipoproteins
Medicine, Traditional
Nigella sativa*
Nigella*
Triglycerides
Apolipoproteins
Apolipoproteins A
Apolipoproteins B
C-Reactive Protein
Cholesterol
Lipoproteins

Reference

1. Olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol. 2008; 61:697–706.

2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595–1607.

3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–2752.

4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49:403–414.

5. Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE, Haffner SM. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005; 112:3713–3721.

6. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007; 86:s836–s842.

7. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract. 2007; 77:251–257.

8. Sharifi F, Mousavinasab SN, Saeini M, Dinmohammadi M. Prevalence of metabolic syndrome in an adult urban population of the west of Iran. Exp Diabetes Res. 2009; 2009:136501.

9. Karimi F, Jahandideh D, Dabbaghmanesh MH, Fattahi MR, Ranjbar Omrani GH. The prevalence of metabolic syndrome and its components among adults in a rural community, Fars, Iran. Int Cardiovasc Res J. 2015; 9:94–99.

10. Maleki F, Sayehmiri F, Kiani F, Sayehmiri K, Nasiri S. Metabolic syndrome prevalence in Iran: a systematic review and meta-analysis. J Kermanshah Univ Med Sci. 2014; 18:242–250.

11. Vimaleswaran KS, Radha V, Mohan V. Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians. Metabolism. 2006; 55:1222–1226.

12. Mohan V, Gokulakrishnan K, Deepa R, Shanthirani CS, Datta M. Association of physical inactivity with components of metabolic syndrome and coronary artery disease--the Chennai Urban Population Study (CUPS no. 15). Diabet Med. 2005; 22:1206–1211.

13. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arch Med Sci. 2008; 4:285–292.

14. Sayed MD. Traditional medicine in health care. J Ethnopharmacol. 1980; 2:19–22.

15. Shrivastava RM, Agrawal RC, Parveen Z. A review on therapeutic applications of Nigella sativa. J Chem Chem Sci. 2011; 1:241–248.

16. Khoddami A, Ghazali HM, Yassoralipour A, Ramakrishnan Y, Ganjloo A. Physicochemical characteristics of nigella seed (Nigella sativa L.) oil as affected by different extraction methods. J Am Oil Chem Soc. 2011; 88:533–540.

17. Najmi A, Nasiruddin M, Khan RA, Haque SF. Effect of Nigella sativa oil on various clinical and biochemical parameters of insulin resistance syndrome. Int J Diabetes Dev Ctries. 2008; 28:11–14.

18. Shah AS, Khan GM, Badshah A, Shah SU, Shah KU, Mirza SA, Shah KU, Khan KA. Nigella sativa provides protection against metabolic syndrome. Afr J Biotechnol. 2012; 11:10919–10925.

19. El-Deeb HM, Elrehany M, Elbawb Elsaid ME, Younis HA. Biochemical effect of Nigella sativa on patients with coronary artery disease. El-Minia Med Bul. 2010; 21:25–36.

20. Datau EA, Wardhana , Surachmanto EE, Pandelaki K, Langi JA, Fias . Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med Indones. 2010; 42:130–134.

21. Mahan LK, Escott-Stump S, Raymond JL. Krause's food and the nutrition care process. 13th ed. St. Louis (MO): Elsevier/Saunders;2012.

22. Najmi A, Haque S, Khan R, Nasiruddin M. Therapeutic effect of Nigella sativa oil on different clinical and biochemical parameters in metabolic syndrome. Internet J Pharmacol. 2008; 5:8.

23. Ibrahim RM, Hamdan NS, Ismail M, Saini SM, Abd Rashid SN, Abd Latiff L, Mahmud R. Protective effects of Nigella sativa on metabolic syndrome in menopausal women. Adv Pharm Bull. 2014; 4:29–33.

24. Husseini MS, Mirkarimi SA, Amini M, Mohtashami R, Kianbakht S, Fallah Hoseini H. Effects of Nigella sativa L. seed oil in type II diabetic Patients: a randomized, double-blind, placebo-controlled clinical trial. J Med Plants. 2013; 12:93–99.

25. Dehkordi FR, Kamkhah AF. Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol. 2008; 22:447–452.

26. Qidwai W, Hamza HB, Qureshi R, Gilani A. Effectiveness, safety, and tolerability of powdered Nigella sativa (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: results of a randomized, double-blind controlled trial. J Altern Complement Med. 2009; 15:639–644.

27. Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH. From here to eternity - the secret of pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther. 2008; 6:495–510.

28. Ibraheim Z. Effect of Nigella sativa seeds and total oil on some blood parameters in female volunteers. Saudi Pharm J. 2002; 10:54–59.

29. Morikawa T, Xu F, Ninomiya K, Matsuda H, Yoshikawa M. Nigellamines A3, A4, A5, and C, new dolabellane-type diterpene alkaloids, with lipid metabolism-promoting activities from the Egyptian medicinal food black cumin. Chem Pharm Bull (Tokyo). 2004; 52:494–497.

30. Ibraheem DA. Comparative study between plant and animal sources of omega-3 fatty acid in their potential role of regulating blood glucose and lipid profile in healthy volunteers. Yemeni J Med Sci. 2011; 5:7–14.

31. Asgari S, Ghandi A, Adibi SH, Dashti G, Naderi GA, Helalat A, Jafari Dinani N. The effects of nigella sativa on atherosclerosis and its new risk factors in hypercholestrolemic rabbits. Iran J Diabetes Lipid Disord. 2007; 6:235–242.